How Sweden's Calliditas Built Up Its US Presence And Development Portfolio

Approval Submission Of Lead Candidate Expected This Quarter

Interview: delivering on its US business strategy during the COVID-19 pandemic has required a focus on communication, according to Calliditas CEO Renee Aguiar-Lucander.  

View of Gamla Stan in the Old Town of Stockholm
The Old Town Of Stockholm • Source: Shutterstock

Calliditas Therapeutics AB planned the commercialization of its first rare disease product, Nefecon (budesonide), in the US, and expanded its development pipeline through its first major product candidate acquisition , as its coped with last year’s COVID-19-related travel restrictions and changing business processes. 

Looking back, CEO Renee Aguiar-Lucander is relieved the Stockholm, Sweden-based company began executing its commercialization strategy relatively early. “We started...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Genitourinary

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Borealis Seeks Aurora In RNA-Based Drugs For Renal Disease

 

With $150m in series A funding, the Versant- and Novartis-backed start-up is betting it can overcome the challenges to getting RNA medicines into the kidney.

Pathalys Raises $105m To Pave Path Toward US Commercialization

 
• By 

The start-up launched last year with Phase III-ready upacicalcet, which has nearly completed two pivotal trials in secondary hyperparathyroidism and for which it has exclusive rights outside of Asia.

Quick Listen: Scrip's Five Must-Know Things

 
• By 

In this week's podcast edition of Five Must-Know Things: Amgen positions for obesity and diabetes; BMS returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer’s crown?; Japan pharma firms cut jobs; and Sun Pharma seeks GLP-1 partner.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.